Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors

US9598423B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Upender Velaparthi · Princeton Junction, US
• Chetan Padmakar Darne · Orange, US
• Peiying Liu · Madison, US
• Mark D. Wittman · Cheshire, US
• Bradley C. Pearce · East Hampton, US
• Erika M. V. Araujo · Woodbridge, US
• Bireshwar Dasgupta · Middletown, US
• Jalathi Surendran Nair · Bengaluru, IN
• Sakthi Kumaran Janakiraman · Bengaluru, IN
• Chandrasekhar Reddy Rachamreddy · Kadapa, IN
• Mallikarjuna Rao Mettu · Bengaluru, IN
• Arul Mozhi Selvan Subbiah Karuppiah · Bengaluru, IN
• Bandreddy Subba Reddy · Bengaluru, IN
• Pulicharla Nagalakshmi · Bengaluru, IN
• Rajesh Onkardas Bora · Bengaluru, IN
• Shilpa Holehatti Maheshwarappa · Savanuru, IN
• Selvakumar Kumaravel · Bengaluru, IN
• Dibakar Mullick · Mahe, IN
• Ramesh Kumar Sistla · Bengaluru, IN

Key dates

• Filing date: Nov 14, 2014
• Grant date: Mar 21, 2017
• Expiry date: Nov 14, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides compounds of Formula (I):and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.